In the absence of hepatic histological data for glucagon‐like peptide‐1 receptor agonists, it is important to explore the effect of these drugs on ALT changes, in available datasets, to gain a better understanding of their potential benefit in NAFLD/NASH. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.